BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8142661)

  • 1. Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs.
    Mitus AJ; Antin JH; Rutherford CJ; McGarigle CJ; Goldberg MA
    Blood; 1994 Apr; 83(7):1952-7. PubMed ID: 8142661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled trial of recombinant human erythropoietin after bone marrow transplantation.
    Link H; Boogaerts MA; Fauser AA; Slavin S; Reiffers J; Gorin NC; Carella AM; Mandelli F; Burdach S; Ferrant A
    Blood; 1994 Nov; 84(10):3327-35. PubMed ID: 7949088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.
    Locatelli F; Zecca M; Pedrazzoli P; Prete L; Quaglini S; Comoli P; De Stefano P; Beguin Y; Robustelli della Cuna G; Severi F
    Bone Marrow Transplant; 1994 Apr; 13(4):403-10. PubMed ID: 8019464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
    Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
    Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation.
    Locatelli F; Zecca M; Beguin Y; Giorgiani G; Ponchio L; De Stefano P; Cazzola M
    Br J Haematol; 1993 Aug; 84(4):752-4. PubMed ID: 8217839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
    Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
    Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients.
    Vannucchi AM; Bosi A; Grossi A; Guidi S; Saccardi R; Lombardini L; Rossi-Ferrini P
    Leukemia; 1992 Mar; 6(3):215-9. PubMed ID: 1564959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of rHuEPO in bone marrow transplantation.
    Klaesson S
    Med Oncol; 1999 Apr; 16(1):2-7. PubMed ID: 10382935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.
    Klaesson S; Ringdén O; Ljungman P; Lönnqvist B; Wennberg L
    Bone Marrow Transplant; 1994 Apr; 13(4):397-402. PubMed ID: 8019463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
    Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
    Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.
    Ayash LJ; Elias A; Hunt M; Demetri G; Wheeler C; Tepler I; Schwartz G; Mazanet R; Reich E; McCauley M
    Br J Haematol; 1994 May; 87(1):153-61. PubMed ID: 7947240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants.
    Beguin Y; Oris R; Fillet G
    Bone Marrow Transplant; 1993 Apr; 11(4):285-92. PubMed ID: 8485476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation.
    Lapierre V; Aupérin A; Tayebi H; Chabod J; Saas P; Michalet M; François S; Garban F; Giraud C; Tramalloni D; Oubouzar N; Blaise D; Kuentz M; Robinet E; Tiberghien P;
    Blood; 2002 Aug; 100(4):1484-9. PubMed ID: 12149235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation.
    Locatelli F; Pedrazzoli P; Barosi G; Zecca M; Porta F; Liberato L; Gambarana D; Nespoli L; Cazzola M
    Br J Haematol; 1992 Apr; 80(4):545-9. PubMed ID: 1581240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating CFU-E during hematopoietic recovery after allogeneic bone marrow transplantation: relationship to erythroid engraftment.
    Vannucchi AM; Bosi A; Lombardini L; Grossi A; Bacci P; Guidi S; Saccardi R; Rossi-Ferrini P
    Exp Hematol; 1995 Dec; 23(13):1337-40. PubMed ID: 7498360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting.
    Lazarus HM; Goodnough LT; Goldwasser E; Long G; Arnold JL; Strohl KP
    Bone Marrow Transplant; 1992 Jul; 10(1):71-5. PubMed ID: 1515882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.
    Baron F; Sautois B; Baudoux E; Matus G; Fillet G; Beguin Y
    Exp Hematol; 2002 Jun; 30(6):546-54. PubMed ID: 12063021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies.
    Irschick EU; Hladik F; Niederwieser D; Nussbaumer W; Holler E; Kaminski E; Huber C
    Blood; 1992 Mar; 79(6):1622-8. PubMed ID: 1547351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the spleen on compartmental levels and distribution of donor progenitor cells after syngeneic and allogeneic bone marrow transplants.
    Shatry AM; Jones M; Levy RB
    Stem Cells Dev; 2004 Feb; 13(1):51-62. PubMed ID: 15068693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.